article thumbnail

Case Study: Two Examples of Successful Automation Integration at Altasciences for Pharmacokinetic Studies

Alta Sciences

About the Author Martin Rougée joined Altasciences in early 2024 as an Optimization Scientist. After completing his doctorate, he moved into the industry by joining a startup that specialized in enzymatic DNA synthesis, where he enhanced their processes and reagents using automated liquid handling technology.

article thumbnail

David Liu receives Breakthrough Prize in Life Sciences

Broad Institute

During his doctoral research at University of California Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He is the 2022 King Faisal Prize Laureate in Medicine, and the recipient of the 2024 Gabbay Award in Biotechnology and Medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Targeting CD40 with bispecifics to outsmart tumours

Drug Target Review

2024: 25(7):853-864. 2024: 84(6). He holds a PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. The Lancet Oncology. Available from: [link] 2 Ellmark P, Deronic A, Hagerbrand K, et al. Available from: [link] 3 Andersson H, Celander M, Ellmark P, et al.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

She earned a doctorate in Pharmacology and the Collaborative Program in Neuroscience from the University of Torontowhere she currently holds an appointment as an Adjunct Professor. In 2024, she was recognized as a PharmaVoice 100 honoree , and named one of the 30 Most Influential People in the Pharma Industry by The Medicine Maker.

article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Studies presented at the American Society of Hematology 2024 Annual Meeting have predicted that patients receiving regular aRBCX would save up to $100,000 per patient lifetime to the healthcare system compared to other transfusion modalities, while increasing quality of life. 2024 Sep 10;2:101875. Blood Adv (2024) 8 (4): 10181029.

article thumbnail

The Long Road to End Tuberculosis

Codon

Based on early successes in animal experiments, doctors tested the vaccine on an infant whose mother had died of TB shortly after giving birth. ” Asimov Press (2024). The infant experienced no adverse effects, thereby suggesting the vaccine was safe. Cite: Nahas, Kamal. “The Long Road to End Tuberculosis.”

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

And though Roche and Bristol Myers acquired both their medicines in high-priced acquisitions, they haven’t yielded significant sales: Rozlytrek generated about 134 million Swiss francs in 2024 , while Augtyro pulled in just $38 million.

FDA